Table 6.
Mortality in association with race/ethnicity among patients with invasive tumors, by tumor site
| Tumor site and Race/ethnicity | Hazard ratio (95% CI) of All-Cause Mortality | Hazard ratio (95% CI) of Cancer-Specific Mortality | |||||
|---|---|---|---|---|---|---|---|
| Model-1 | Model-2 | Model-3 | Model-1 | Model-2 | Model-3 | ||
| Breast | |||||||
| NH-Black | 1.4(1.2–1.8) | 1.2(1.0–1.6) | 1.7(1.1–2.5) | 1.2(0.9–1.6) | 1.1(0.8–1.5) | 1.4(0.8–2.4) | |
| NH-API | 0.6(0.4–0.8) | 0.5(0.4–0.9) | 0.6(0.3–1.1) | 0.6(0.3–1.0) | 0.6(0.3–1.1) | 0.8(0.4–1.7) | |
| Hispanic | 1.0(0.7–1.4) | 0.9(0.7–1.2) | 1.1(0.7–1.7) | 0.8(0.5–1.3) | 0.7(0.5–1.2) | 0.8(0.4–1.5) | |
| AI/AN | 0.1(0.0–30.2) | 0.1(0.0–29.3.3) | undefined | 0.1(0.0 –45.2) | 0.1(0.0–55.5) | undefined | |
| Colorectal | |||||||
| NH-Black | 1.4(1.1–1.7) | 1.2(1.0–1.5) | 1.2(0.9–1.7) | 1.4(1.1–1.8) | 1.2(1.0–1.6) | 1.2(0.8–1.8) | |
| NH-API | 0.9(0.7–1.1) | 0.9(0.7–1.1) | 0.9(0.6–1.3) | 0.8(0.6–1.2) | 0.9(0.6–1.2) | 0.9(0.6–1.5) | |
| Hispanic | 1.1(0.8–1.4) | 1.0(0.8–1.3) | 1.0(0.7–1.5) | 1.1(0.8–1.5) | 1.0(0.7–1.3) | 1.1(0.7–1.6) | |
| AI/AN | 4.4(1.8–10.9) | 4.8(1.9–11.9) | 4.9(1.9–12.7) | 6.1(2.5–15.1) | 7.0(2.8–17.4) | 6.6(2.6–17.2) | |
| Prostate | |||||||
| NH-Black | 1.2(1.1–1.5) | 1.0(0.9–1.2) | 1.1(0.9–1.4) | 1.5(1.2–1.8) | 1.3(1.0–1.6) | 1.7(1.2–2.3) | |
| NH-API | 0.8(0.6–1.1) | 0.8(0.6–1.1) | 0.7(0.5–1.2) | 0.5(0.3–0.9) | 0.5(0.3–0.9) | 0.4(0.2–0.9) | |
| Hispanic | 0.8(0.6–1.1) | 0.7(0.5–0.9) | 0.4(0.3–0.8) | 0.9(0.6–1.4) | 0.8(0.5–1.2) | 0.4(0.2–0.9) | |
| AI/AN | 2.0(0.7–5.3) | 1.8(0.7–4.8) | 2.2(0.7–6.9) | 1.6(0.3–8.2) | 1.5(0.3–7.4) | 1.7(0.3–9.7) | |
| Lung and bronchus | |||||||
| NH-Black | 1.1(1.0–1.3) | 1.0(0.9–1.2) | 1.1(0.9–1.3) | 1.1(1.0–1.3) | 1.1(0.9–1.2) | 1.1(0.9–1.3) | |
| NH-API | 0.8(0.7–1.0) | 0.8(0.7–1.1) | 0.9(0.6–1.2) | 0.8(0.6–1.0) | 0.8(0.6–1.0) | 0.8(0.5–1.1) | |
| Hispanic | 1.0(0.8–1.2) | 0.9(0.7–1.1) | 0.8(0.6–1.1) | 1.0(0.8–1.3) | 0.9(0.7–1.2) | 0.8(0.6–1.2) | |
| AI/AN | 2.8(1.3–5.8) | 2.1(1.0–4.4) | 1.7(0.7–4.3) | 3.1(1.4–6.7) | 2.4(1.1–5.2) | 2.0(0.8–5.2) | |
| Cervical | |||||||
| NH-Black | 0.6(0.2–1.4) | 0.4(0.2–1.2) | 0.1(0.0–0.5) | 0.4(0.2–1.3) | 0.4(0.1–1.4) | 0.7(0.1–5.8) | |
| NH-API | 1.6(0.6–4.3) | 1.6(0.6–4.7) | 2.3(0.3–19.7) | 2.3(0.8–6.4) | 2.1(0.7–6.8) | 3.5(0.4–30.4) | |
| Hispanic | 1.1(0.5–2.3) | 1.0(0.4–2.3) | 2.7(0.6–12.6) | 1.3(0.6–3.0) | 1.2(0.4–3.0) | 1.4(0.2–17.1) | |
| AI/AN | 2.2(0.2–21.3) | 1.1(0.1–13.8) | 5.6(0.0–>99) | 2.4(0.1–69.0) | 3.3(0.1–>99) | 408.7(6.6–>999) | |
| Ovarian | |||||||
| NH-Black | 1.2(0.8–1.9) | 1.2(0.8–1.9) | 1.5(0.8–3.0) | 1.1(0.7–1.9) | 1.2(0.7–2.0) | 1.3(0.6–2.6) | |
| NH-API | 0.3(0.1–0.9) | 0.3(0.1–1.0) | 0.2(0.0–1.5) | 0.4(0.1–1.1) | 0.4(0.1–1.1) | 0.3(0.0–1.7) | |
| Hispanic | 0.9(0.5–1.7) | 0.9(0.5–1.6) | 1.3(0.6–3.2) | 0.8(0.4–1.5) | 0.7(0.3–1.4) | 0.9(0.3–2.7) | |
| AI/AN | 1.4(0.3–7.3) | 2.2(0.4–12.5) | undefined | 1.6(0.3–8.1) | 3.0(0.5–17.5) | undefined | |
| Melanoma of the skin | |||||||
| NH-Black | 1.7(0.3–8.3) | 1.6(0.3–8.2) | undefined | 3.6(0.7–18.3) | 3.5(0.7–18.4) | undefined | |
| NH-API | 4.3(1.5–11.9) | 4.7(1.6–13.4) | 2.5(0.6–11.1) | 4.9(1.5–15.6) | 5.3(1.6–17.3) | 0.8(0.1–5.3) | |
| Hispanic | 3.4(1.2–9.9) | 4.2(1.5–12.4) | 1.5(0.3–7.7) | 4.5(1.5–13.7) | 6.5(2.2–19.6) | 1.5 (0.3–9.2) | |
| AI/AN | 5.8(0.6–59.0) | 3.5(0.3–42.1) | 6.8(0.4–103.4) | undefined | undefined | undefined | |
| Urinary Bladder | |||||||
| NH-Black | 1.5(1.0–2.4) | 1.3(0.8–2.0) | 2.0(1.0–4.4) | 1.8(1.0–3.1) | 1.7(0.9–3.0) | 2.3(0.9–6.0) | |
| NH-API | 0.9(0.5–1.5) | 0.9(0.5–1.6) | 1.3(0.6–2.7) | 0.9(0.4–2.1) | 1.0(0.4–2.2) | 1.2(0.4–3.9) | |
| Hispanic | 0.7(0.3–1.5) | 0.6(0.3–1.4) | 0.6(0.2–1.8) | 0.7(0.2–2.1) | 0.7(0.2–2.1) | 0.7(0.2–2.9) | |
| AI/AN | 0.5(0.1–1.8) | 0.7(0.2–2.5) | 0.5(0.1–2.6) | 0.3(0.0–3.0) | 0.5(0.1–4.7) | undefined | |
*
Non-Hispanic (NH) whites as reference in all models. Model-1: Hazard ratio (HR) adjusted for age, sex, tumor stage, surgery, and radiotherapy. Model-2: HR additionally adjusted for education, poverty and family income. Model-3: HR additionally adjusted for health insurance in subjects with data on health insurance.